Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Roche Diagnostics, Asuragen, Mission Bio

Roche Diagnostics Navify Mutation Profiler, Navify Therapy Matcher

Roche Diagnostics has launched Navify Mutational Profiler and Navify Therapy Matcher to support next-generation sequencing-based cancer genomic profiling tests. Both are part of Roche's Navify Decision Support portfolio.

Navify Mutational Profiler is a clinical software that provides annotation, interpretation, and clinical reporting of NGS tests. Navify Therapy Matcher is an optional clinical decision support app that helps clinicians link clinically actionable mutations to therapy options.


Asuragen AmplideX PCR/CESMN1/2 Kit

Asuragen has launched the AmplideX PCR/CE SMN1/2 kit. Building upon the testing workflow of the AmplideX PCR/CE SMN1 Kit, the new assay quantifies both SMN1 and SMN2 exon 7 copy number in less than four hours from a single PCR reaction. The firm said that the assay shares a common testing workflow with all other assays in the AmplideX portfolio and is similarly optimized for broadly installed Thermo Fisher Scientific Applied Biosystems Genetic Analyzers.

Interest in SMN1 and SMN2 copy number quantification has grown following the 2016 FDA approval of nusinersen (Biogen Idec's Spinraza) for the treatment of spinal muscular atrophy, a disease attributable to loss of functional copies of the SMN1 gene, and the severity of which is inversely correlated with the number of copies of SMN2, Asuragen noted.


Mission Bio Tapestri Designer

Mission Bio has launched Tapestri Designer, a cloud-based tool for customers to design and order single-cell DNA panels. The tool makes use of artificial intelligence and machine learning to enable customers to order customized gene panels, reducing turnaround time for panel design to minutes from weeks, according to the company. Tapestri Designer allows researchers to complete custom designs in three steps: set up an account; upload a CSV file or enter a gene, ID, or coordinate targets; and submit a design to receive results.


For more new products and services, please visit the New Products page on our website.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.